Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1979 Aug;32(8):832–844. doi: 10.1136/jcp.32.8.832

Bone aluminium in haemodialysed patients and in rats injected with aluminium chloride: relationship to impaired bone mineralisation.

H A Ellis, J H McCarthy, J Herrington
PMCID: PMC1145818  PMID: 389958

Abstract

Iliac bone aluminium was determined by neutron activation analysis in 34 patients with chronic renal failure and in eight control subjects. In 17 patients treated by haemodialysis there was a significant increase in the amount of aluminium (mean +/- SE = 152 +/- 30 ppm bone ash). In eight patients treated by haemodialysis and subsequent renal transplantation, bone aluminium was still significantly increased (92 +/- 4.5 ppm bone ash) but was less than in the haemodialysed patients. In some patients aluminium persisted in bone for many years after successful renal transplantation. There was no relationship between hyperparathyroidism and bone aluminium. Although no statistically significant relationship was found between the mineralisation status of bone and bone aluminium, patients dialysed for the longest periods tended to be those with the highest levels of aluminium, osteomalacia, and dialysis encephalopathy. In 20 rats given daily intraperitoneal injections of aluminium chloride for periods of up to three months, there was accumulation of aluminium in bone (163 +/- 9 ppm ash) to levels comparable to those obtained in the dialysis patients, and after about eight weeks osteomalacia developed. The increased bone aluminium and osteomalacia persisted after injections had been stopped for up to 49 days, although endochondral ossification was restored to normal. As a working hypothesis it is suggested that aluminium retained in the bone of the dialysis patients and the experimental animals interferes with normal mineralisation.

Full text

PDF
832

Images in this article

839Fig. 5
on p.839
840Fig. 6
on p.840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alfrey A. C., LeGendre G. R., Kaehny W. D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med. 1976 Jan 22;294(4):184–188. doi: 10.1056/NEJM197601222940402. [DOI] [PubMed] [Google Scholar]
  2. Berlyne G. M., Ben-Ari J., Pest D., Weinberger J., Stern M., Levine R., Gilmore G. R. Hyperaluminaemia from aluminum resins in renal failure. Lancet. 1970 Sep 5;2(7671):494–496. doi: 10.1016/s0140-6736(70)90113-3. [DOI] [PubMed] [Google Scholar]
  3. Berlyne G. M., Yagil R., Ari J. B., Weinberger G., Knopf E., Danovitch G. M. Aluminium toxicity in rats. Lancet. 1972 Mar 11;1(7750):564–568. doi: 10.1016/s0140-6736(72)90357-1. [DOI] [PubMed] [Google Scholar]
  4. Elliott H. L., Dryburgh F., Fell G. S., Sabet S., Macdougall A. I. Aluminium toxicity during regular haemodialysis. Br Med J. 1978 Apr 29;1(6120):1101–1103. doi: 10.1136/bmj.1.6120.1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ellis H. A., Peart K. M. Azotaemic renal osteodystrophy: a quantitative study on iliac bone. J Clin Pathol. 1973 Feb;26(2):83–101. doi: 10.1136/jcp.26.2.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ellis H. A., Peart K. M. Dextran sulphate osteopathy in parathyroidectomized rats. Br J Exp Pathol. 1971 Dec;52(6):684–695. [PMC free article] [PubMed] [Google Scholar]
  7. McDermott J. R., Smith A. I., Ward M. K., Parkinson I. S., Kerr D. N. Brain-aluminium concentration in dialysis encephalopathy. Lancet. 1978 Apr 29;1(8070):901–904. doi: 10.1016/s0140-6736(78)90681-5. [DOI] [PubMed] [Google Scholar]
  8. Ondreicka R., Ginter E., Kortus J. Chronic toxicity of aluminium in rats and mice and its effects on phosphorus metabolism. Br J Ind Med. 1966 Oct;23(4):305–312. doi: 10.1136/oem.23.4.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Parsons V., Davies C., Goode C., Ogg C., Siddiqui J. Aluminium in bone from patients with renal failure. Br Med J. 1971 Oct 30;4(5782):273–275. doi: 10.1136/bmj.4.5782.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pierides A. M., Ellis H. A., Simpson W., Dewar J. H., Ward M. K., Kerr D. N. Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy. Lancet. 1976 May 22;1(7969):1092–1095. doi: 10.1016/s0140-6736(76)90061-1. [DOI] [PubMed] [Google Scholar]
  11. Platts M. M., Goode G. C., Hislop J. S. Composition of the domestic water supply and the incidence of fractures and encephalopathy in patients on home dialysis. Br Med J. 1977 Sep 10;2(6088):657–660. doi: 10.1136/bmj.2.6088.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Thurston H., Gilmore G. R., Swales J. D. Aluminium retention and toxicity in chronic renal failure. Lancet. 1972 Apr 22;1(7756):881–883. doi: 10.1016/s0140-6736(72)90743-x. [DOI] [PubMed] [Google Scholar]
  13. Ward M. K., Feest T. G., Ellis H. A., Parkinson I. S., Kerr D. N. Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium. Lancet. 1978 Apr 22;1(8069):841–845. doi: 10.1016/s0140-6736(78)90191-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES